![[IPWatchdog Logo]](https://ipwatchdog.com/wp-content/themes/IPWatchdog%20-%202023/assets/images/temp/logo-small@2x.png){kind=logo}
Jonathan B. (J.B.) Fitzgerald, Ph.D.
Counsel
Jonathan B. (J.B.) Fitzgerald, Ph.D. is counsel at Snell & Wilmer. His primary practice area involves preparing and prosecuting patent applications in the biotechnology and the life sciences fields. As part of his practice, J.B. helps manage worldwide patent portfolios, which requires prosecuting patents in a variety of different countries and jurisdictions throughout the world. His practice also includes performing freedom to operate analysis and prosecuting trademark applications.
Recent Articles by Jonathan B. (J.B.) Fitzgerald, Ph.D.
As previously reported here, on February 28, 2022, in Interference 106,115, the Patent Trial and Appeal Board (PTAB) issued a decision in which it awarded inventive priority to the Broad Institute (Broad) over the University of California (U.C.) on an invention covering applications of the CRISPR-Cas9 gene editing system in eukaryotic cells. This decision purports to award substantial control of the CRISPR-Cas9 patent landscape to Broad. This article provides additional background on CRISPR-Cas9 technology, outlines the critical findings in Interference 106,115 that resulted in the PTAB awarding priority to Broad, and describes the impact of the PTAB’s decision for Broad, U.C., and other companies involved in the development of CRISPR-Cas9 technology.
